LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Aurelio Sahagun: New President of MicroPort Orthopedics
People In The News

Aurelio Sahagun: New President of MicroPort Orthopedics

September 24, 2015 2 min read Premium comments

Advertisement

Aurelio Sahagun: New President of MicroPort Orthopedics
Aurelio Sahagun

Aurelio Sahagun has been tapped to lead MicroPort Scientific Corporation into the future. Sahagun has assumed the role of President. Ted Davis has departed as chief executive officer, but has committed to working closely with Sahagun to ensure a smooth and seamless transition.

Sahagun joined MicroPort Orthopedics in January 2014 as vice president international; he was then promoted to chief operations officer of the company. Sahagun has also been a member of MicroPort Scientific’s Intercontinental Executive Committee since its inception in early 2014.

According to the September 9, 2015 news release, Sahagun was formerly with Wright Medical as the corporate officer and the vice president of Europe, Middle East and Africa Commercial Operations since 2011, and had previously served as vice president of sales for the region since 2010. He joined Wright Medical in early 2006 as director of finance and operations in France, and served as both director of finance of EMEA and vice president of finance of EMEA prior to the positions above. Before Wright Medical, Sahagun worked for Medtronic where he provided senior financial support to the company’s spine business across Europe.

Sahagun earned an MBA degree at HEC (Paris, France), a Bachelor’s degree in Economics from UAM (Autonomous University of Madrid, Spain), and has participated in Executive Education programs at Stanford Graduate School of Business (Stanford, California) and Harvard Business School (Cambridge, Massachusetts).

Aurelio Sahagun told OTW, “As we move forward, sales will be our number one focus. Supporting our commercial efforts will guide most of our key business decisions, and we will keep building on our proven and differentiated technologies: our hip portfolio includes some of the most advanced tissue sparing techniques, and our Medial Pivot knee offering provides enhanced quadricep efficiency; these techniques are fast forwarding the process of recovery and allowing patients to return to increased activity levels at an accelerated rate.”

“While we grow our business we will continue to maintain a rigorous control over our spending, maximizing the return on the investments that will allow us to reach our corporate profitability targets; every employee in our company contributes to our revenue efforts, and we will be very intentional about creating the appropriate company culture that reflects so.”

“I have the chance of working with a very strong executive team, and we will be the reflection of how we expect our company to behave: with one voice and supportive of each other. I am confident in the bright future we have ahead of us. Through open dialogue, a culture of empowerment and accountability, and a high sense of urgency, I have no doubt in our ability to materially grow our business and foster across our company and with our customers a sense of pride working for and with MicroPort Orthopedics.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy